Heron Therapeutics | HRTX - Ebit

Stock Price
0.78
Daily Change
0.02 2.39%
Monthly
-34.73%
Yearly
-65.79%
Q1 Forecast
0.76

Heron Therapeutics reported $38K in EBIT for its fiscal quarter ending in December of 2025.





Ebit Change Date
ALKERMES USD -10.95M 100.03M Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amarin USD -2.26M 564K Dec/2025
ANI Pharmaceuticals USD 29.13M 6.3M Dec/2025
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD 40.81M 17.01M Dec/2025
Eisai JPY 20.03B 6.36B Dec/2025
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Heron Therapeutics USD 38K 3.83M Dec/2025
Insmed USD -249.71M 11.64M Dec/2025
Ligand Pharmaceuticals USD 158.89M 115.32M Sep/2025
Merck USD 6.24B 1.32B Dec/2025
Nektar Therapeutics USD -34.34M 3.68M Sep/2024
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Omeros USD -48.15M 7.25M Sep/2023
Pacira USD 3.19M 9.96M Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 2.1B Dec/2025
Surmodics USD -322K 2.13M Dec/2023
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Veracyte USD 24.63M 1.52M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025